INBS

Business Context and Reporting Period

Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended September 30, 2024
Business Overview: A medical technology company focused on non-invasive testing solutions. Operations are divided into two segments: the commercially available Intelligent Fingerprinting Products (IFPG) segment, which generates all current revenue, and the Development Stage Biosensor Platform Technology (BPT) segment.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased by $76,193 (9.6%) driven by customer base expansion in existing and new markets. Cartridge sales rose to $448,514 from $380,059.
• Cost Efficiency: Cost of revenue decreased by $38,277 due to reductions in direct labor and overhead costs, improving gross margin from 29.18% to 39.76%.
• Operating Expenses: Total operating expenses increased by $329,623. This was primarily driven by a significant increase in "Development and regulatory approval expenses" ($948,752 vs. $103,947), attributed to in-house R&D staff and clinical study costs for the FDA 510(k) submission. Conversely, SG&A expenses decreased by $508,044 due to reduced legal and consultancy costs.
• Other Income: Government support income increased to $126,128 from $109,871, largely due to R&D tax refunds. Interest income surged to $52,840 from $139 due to higher cash balances from capital raising.
• Foreign Exchange: The company recorded a foreign currency translation gain of $216,355, compared to a loss of $18,016 in the prior year, due to favorable exchange rates.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months. Cash on hand ($3.99 million) may be insufficient to fund the operating plan without additional financing.
• Capital Raising: On September 18, 2024, the company entered an At-The-Market (ATM) offering agreement to sell up to $3.0 million of common stock. Approximately $34,511 was raised in the first two weeks of the agreement.
• Regulatory Milestones: The company successfully completed in-clinic testing and biocompatibility testing required for its FDA 510(k) submission, which is planned for the fourth quarter of 2024. Clearance is targeted for the 2025 calendar year.
• Grant Risks: The company holds a grant from the Australian Government with an extended deadline of March 28, 2025. Failure to meet remaining milestones could require a refund of grant proceeds.
• Internal Controls: The company disclosed that its disclosure controls and procedures were ineffective as of September 30, 2024, due to material weaknesses in the control environment, risk assessment, and monitoring.

Investor Verification Checklist

• Liquidity Runway: Verify the sufficiency of the $3.99 million cash balance against the burn rate, considering the substantial doubt regarding the going concern status.
• ATM Offering Progress: Monitor the utilization of the $3.0 million ATM facility to determine if it will be sufficient to fund operations through the next 12 months.
• FDA Submission Timeline: Confirm the submission date of the 510(k) application and the likelihood of approval in 2025, as this is critical for US market entry.
• Grant Milestones: Assess the progress toward the remaining 4 milestones of the Australian Government grant to avoid potential clawbacks.
• Remediation of Controls: Review the company's progress in addressing the material weaknesses in internal controls over financial reporting.